Despite how common GLP-1 use has become, there has been relatively little dermatology-focused research on their cutaneous side effects, with most of the existing literature limited to individual case reports. For the cross-sectional analysis, Fat and colleagues compared cutaneous adverse events reported in the FDA Adverse Event Reporting System (FAERS) for the GLP-1 receptor agonists semaglutide (Ozempic/ Wegovy, Novo Nordisk), liraglutide, exenatide and dulaglutide (Trulicity, Eli Lilly) with cutaneous adverse event reports for the dipeptidyl peptidase-4 (DPP-IV) inhibitors sitagliptin, saxagliptin, linagliptin and alogliptin
Compounding pharmacies have begun selling unregulated versions of semaglutide
In the body, it has an impact on a few different features
Abbasinejad recognizes that Ozempic has a strong track record for helping individuals lose significant weight, particularly due to its ability to reduce appetite and improve fat metabolism
It is not a drug, food, cosmetic, or supplement